Lutetium-177MeSH Supplementary Concept

https://www.ema.europa.eu/en/medicines/human/EPAR/theralugand
2025
false
false
false
Netherlands
French
English
syndication feed
syndication feed
summary of product characteristics
summary of product characteristics
package leaflet
package leaflet
drug evaluation
drug evaluation
Lutetium (177Lu) chloride
Lutetium (177Lu) chloride
Lutetium-177
Lutetium-177
Radioisotopic Labeling
Radioisotopic Labeling
drug approval
drug approval
europe
europe
risk management
risk management
Precursor Radiopharmaceutical Dosage Form
Precursor Radiopharmaceutical Dosage Form

---
https://www.has-sante.fr/jcms/p_3518264/fr/lunca-chlorure-de-lutetium-177lu-precurseur-radiopharmaceutique
2024
false
false
false
France
insurance, health, reimbursement
insurance, health, reimbursement
Radioisotopic Labeling
Radioisotopic Labeling
evaluation of the transparency committee
evaluation of the transparency committee
Precursor Radiopharmaceutical Dosage Form
Precursor Radiopharmaceutical Dosage Form
Lutetium-177
Lutetium-177
radiopharmaceuticals
radiopharmaceuticals
lutetium
lutetium
chlorides
chlorides

---
https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto
2023
false
false
false
Netherlands
French
English
treatment outcome
treatment outcome
syndication feed
syndication feed
summary of product characteristics
summary of product characteristics
package leaflet
package leaflet
drug evaluation
drug evaluation
drug approval
drug approval
europe
europe
radiopharmaceuticals
radiopharmaceuticals
Lutetium Lu 177 Vipivotide Tetraxetan
Lutetium Lu 177 Vipivotide Tetraxetan
Lutetium Lu 177 Vipivotide Tetraxetan
Lutetium Lu 177 Vipivotide Tetraxetan
lutetium (177Lu) vipivotide tetraxetan
lutetium (177Lu) vipivotide tetraxetan
radiopharmaceuticals
radiopharmaceuticals
radiopharmaceuticals
radiopharmaceuticals
Lutetium-177
Lutetium-177
prostatic neoplasms, Castration-Resistant
prostatic neoplasms, Castration-Resistant
neoplasm metastasis
neoplasm metastasis
PSMA-Positive Tumor
PSMA-Positive Tumor
antineoplastic combined chemotherapy protocols
antineoplastic combined chemotherapy protocols
injections, intravenous
injections, intravenous
infusions, intravenous
infusions, intravenous
FOLH1 protein, human
FOLH1 protein, human
product surveillance, postmarketing
product surveillance, postmarketing
pregnancy
pregnancy
breast feeding
breast feeding

---
https://www.has-sante.fr/jcms/p_3434491/fr/endolucin-beta-chlorure-de-lutetium-177-lu-no-carrier-added-n-c-a-precurseur-radiopharmaceutique
2023
false
false
false
France
Radiopharmaceutical precursor (qualifier value)
Radioisotopic Labeling
insurance, health, reimbursement
evaluation of the transparency committee
Lutetium-177
lutetium

---
https://www.ema.europa.eu/en/medicines/human/EPAR/illuzyce
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
syndication feed
summary of product characteristics
summary of product characteristics
package leaflet
package leaflet
drug evaluation
drug evaluation
Lutetium-177
Radioisotopic Labeling
drug approval
europe
neuroendocrine tumors
prostatic neoplasms
radiopharmaceuticals
other therapeutic radiopharmaceuticals
Precursor Radiopharmaceutical Solution Dosage Form

---